Insulin Therapy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Insulin therapy involves the subcutaneous (or in acute settings, intravenous) administration of exogenous insulin to regulate blood glucose levels. Insulin is a peptide hormone produced by pancreatic beta cells that enables cellular glucose uptake, suppresses hepatic glucose production, promotes glycogen synthesis, and inhibits lipolysis and ketogenesis.

Insulin therapy is the cornerstone of management for type 1 diabetes mellitus (T1DM), where autoimmune destruction of pancreatic beta cells results in absolute insulin deficiency. Without exogenous insulin, patients with T1DM develop life-threatening diabetic ketoacidosis (DKA). In type 2 diabetes mellitus (T2DM), insulin is initiated when lifestyle modification and oral/non-insulin injectable agents (particularly GLP-1 receptor agonists) are insufficient to achieve glycaemic targets — typically reflecting progressive beta cell failure.

The pharmacological landscape of insulin has evolved dramatically since the introduction of human recombinant insulin (replacing animal insulins) and, subsequently, insulin analogues — engineered modifications to the insulin molecule that produce more predictable and physiological pharmacokinetic profiles. Modern insulin analogues include rapid-acting, short-acting, intermediate-acting, and long-acting (basal) formulations, plus premixed combinations. Each differs in onset, peak, and duration of action, enabling regimen customisation to match a patient's lifestyle, carbohydrate intake, and glycaemic patterns.

The parallel development of continuous glucose monitoring (CGM) technology and automated insulin delivery (AID) systems — also called artificial pancreas or closed-loop systems — has transformed insulin therapy in T1DM, enabling real-time glucose-responsive insulin delivery that significantly reduces both hyperglycaemia and hypoglycaemia burden compared to traditional injection-based regimens.

All insulin therapies are guided by the ADA (American Diabetes Association) and EASD (European Association for the Study of Diabetes) consensus guidelines (2023 update), which provide the most current evidence-based recommendations for pharmacological management of T2DM, and by the ADA Standards of Medical Care in Diabetes 2024.

Insulin therapy is indicated across a spectrum of clinical conditions involving absolute or relative insulin deficiency:

Type 1 Diabetes Mellitus (T1DM)

Insulin is mandatory and life-sustaining in T1DM. All people with T1DM require exogenous insulin from diagnosis. The standard of care is a basal-bolus insulin regimen or automated insulin delivery (AID) system. There is no alternative to insulin in T1DM; oral agents cannot replace it. Prevalence: approximately 5-10% of all diabetes cases globally; typically presents in childhood, adolescence, or young adulthood but can occur at any age.

Type 2 Diabetes Mellitus (T2DM)

Insulin is initiated in T2DM when:

• HbA1c remains above target despite optimised doses of multiple oral and non-insulin injectable agents
• There is severe symptomatic hyperglycaemia (HbA1c >10%, symptoms of polyuria, polydipsia, weight loss)
• Significant beta cell failure has occurred (low C-peptide levels)
• Certain comorbidities preclude preferred non-insulin agents

The ADA/EASD 2023 consensus recommends that GLP-1 receptor agonists (semaglutide, liraglutide) and/or SGLT2 inhibitors be used before insulin where appropriate due to their proven cardiorenal protective effects. Insulin may be combined with these agents.

Gestational Diabetes Mellitus (GDM)

Insulin is the preferred pharmacological treatment for GDM when dietary management is insufficient. Metformin may be used but crosses the placenta; insulin does not cross and has an established safety record. Insulin requirements typically increase through the second and third trimesters due to rising insulin resistance.

Other Indications

• Pancreatogenic (Type 3c) diabetes: Following pancreatitis, pancreatectomy, or pancreatic cancer, insulin deficiency may require exogenous replacement. Hypoglycaemia risk is high due to concurrent glucagon deficiency.
• Perioperative management: Insulin infusion or subcutaneous regimens manage hyperglycaemia during surgery and critical illness, where oral agents are inappropriate.
• Hyperosmolar hyperglycaemic state (HHS) and DKA: Intravenous insulin infusion is the cornerstone of acute management.
• Steroid-induced hyperglycaemia: High-dose corticosteroids cause postprandial glucose elevation; insulin — particularly prandial (bolus) insulin — corrects this pattern.
• Cystic fibrosis-related diabetes (CFRD): Insulin is the only recommended pharmacological treatment for CFRD.

The decision to initiate insulin and choose the appropriate regimen requires clinical assessment of diabetes type, degree of beta cell function, glycaemic targets, lifestyle factors, hypoglycaemia risk, patient preference, and healthcare access.

Assessment Before Insulin Initiation

• HbA1c and current glycaemic control: Baseline HbA1c guides initial dose and urgency. Very high HbA1c (>10% / 86 mmol/mol) may require early insulin initiation alongside or instead of oral agents
• C-peptide levels: C-peptide is co-secreted with endogenous insulin and reflects residual beta cell function. Low C-peptide confirms absolute insulin deficiency (T1DM or advanced T2DM), supporting insulin need. C-peptide above 0.6 nmol/L (alongside positive islet autoantibodies) supports T1DM diagnosis.
• Islet autoantibodies (GADA, ZnT8A, IA-2A): Positive antibodies in a patient diagnosed as T2DM should prompt reclassification to latent autoimmune diabetes of adults (LADA/Type 1.5), where insulin is eventually required
• Renal and hepatic function: eGFR affects the choice and dose of non-insulin agents; metformin and SGLT2 inhibitors have eGFR thresholds below which they cannot be used, often making insulin the default
• Hypoglycaemia risk assessment: History of severe hypoglycaemia, hypoglycaemia unawareness, occupational risk (heavy machinery, driving), or elderly patients with cognitive impairment require more conservative glycaemic targets and simplified regimens
• Patient preference, literacy, and dexterity: Basal-bolus regimens require multiple daily injections and carbohydrate counting; basal-only or premixed regimens may be more appropriate for patients with limitations in these areas

Glycaemic Targets

The standard HbA1c target for most non-pregnant adults with diabetes is below 7% (53 mmol/mol). Targets are individualised: more stringent targets (<6.5%) may be appropriate in younger patients with long life expectancy and low hypoglycaemia risk; less stringent targets (7.5-8.0%) are appropriate in older adults with comorbidities, limited life expectancy, or hypoglycaemia unawareness. CGM targets: Time in Range (TIR, 3.9-10 mmol/L) >70%; Time Below Range (<3.9 mmol/L) <4%.

Modern insulin therapy offers a broad range of products and delivery systems matched to different clinical needs.

Rapid-Acting Insulin Analogues (Prandial / Bolus)

These are administered at mealtimes (0-15 minutes before, or immediately after) to match postprandial glucose rise:

• Insulin lispro (Humalog, Admelog): Onset 15 min, peak 1-2 hours, duration 3-4 hours
• Insulin aspart (NovoRapid/NovoLog, Fiasp): Standard aspart — onset 15 min; Fiasp (faster aspart with niacinamide) — onset 2.5 min, peak 1-1.5 hours; useful for post-meal injection
• Insulin glulisine (Apidra): Onset 15 min, peak 1-1.5 hours, duration 3-4 hours

Basal (Long-Acting) Insulin Analogues

Provide steady background insulin suppressing hepatic glucose production overnight and between meals:

• Insulin glargine U100 (Lantus, Basaglar, Toujeo-precursor): Once daily; peakless 20-24 hour profile; the most widely used basal insulin globally
• Insulin glargine U300 (Toujeo): More concentrated (300 units/mL); same molecule as U100 glargine but slower absorption; slightly longer duration (>24 hours); less day-to-day variability; marginally lower nocturnal hypoglycaemia versus U100
• Insulin degludec (Tresiba) U100/U200: Ultra-long action (>42 hours); forms stable multi-hexamer subcutaneous depot; lowest day-to-day variability of all basal insulins; allows flexible dosing timing; significantly lower nocturnal hypoglycaemia versus glargine U100 in T1DM (SWITCH trials)

Premixed Insulins

Fixed-ratio combinations of rapid/short-acting and intermediate-acting insulins, administered twice daily (before breakfast and dinner). Examples: NovoMix 30 (30% aspart/70% protamine aspart), Humalog Mix 25 (25% lispro/75% lispro protamine). Simpler regimen — fewer injections — but less flexible than basal-bolus; increased hypoglycaemia risk and poorer HbA1c outcomes versus basal-bolus in most T1DM patients.

Regimen Types

• Basal-bolus (multiple daily injection — MDI) regimen: One to two injections of basal insulin plus rapid-acting bolus insulin with each meal (typically 3 bolus injections per day). Closest to physiological insulin secretion; most flexible for varying mealtimes and carbohydrate intake; requires dose calculation and carbohydrate awareness. The recommended regimen for T1DM.
• Basal-only regimen: A single daily basal insulin injection, typically used to initiate insulin in T2DM alongside oral agents. Starting dose 10 units or 0.1-0.2 units/kg/day, titrated every 3 days by 2 units until fasting glucose is within target (4.4-7.2 mmol/L).
• Premixed twice-daily regimen: Simpler regimen suited to T2DM patients with regular lifestyle and consistent meal patterns who cannot manage basal-bolus. Less suitable for T1DM.

Continuous Glucose Monitoring (CGM)

• FreeStyle Libre 3 (Abbott): Continuous wear glucose sensor (14-day, factory-calibrated, no finger-prick required); transmits readings to smartphone every minute; provides glucose direction arrows and alarms; widely used globally; available on prescription in many countries
• Dexcom G7: 10-day sensor with 30-minute warm-up; real-time alarms for rapidly changing glucose; direct Bluetooth to phone without separate receiver; integrated with most closed-loop systems
• CGM metrics: Time in Range (TIR), Time Below Range (TBR), GMI (Glucose Management Indicator, an HbA1c approximation from CGM data), and coefficient of variation (CV) for glycaemic variability assessment

Automated Insulin Delivery (AID) Systems — Closed-Loop / Artificial Pancreas

• CamAPS FX (CamDiab): CE-marked hybrid closed-loop algorithm (from Cambridge University) running on Android smartphone, compatible with Dexcom G6/G7 and Dana RS/RS2 or YpsoPump pumps. Studies show TIR improvement from 55% to 73% versus sensor-augmented pump therapy in T1DM adults. Also licensed for T1DM children and pregnant women with T1DM.
• Omnipod 5 (Insulet): Tubeless patch pump with integrated automated insulin delivery; uses Dexcom G6; FDA-approved and CE-marked; adjusts basal insulin delivery every 5 minutes based on CGM algorithm; approved for T1DM from age 2 years.

When appropriately prescribed and managed, insulin therapy delivers critical clinical and quality-of-life benefits across diabetes populations:

• Life-sustaining in T1DM: Insulin is the only treatment preventing DKA and death in T1DM. Without it, patients cannot survive. This is not a treatment choice but a physiological necessity.
• Glycaemic control prevents microvascular complications: The landmark DCCT trial (Diabetes Control and Complications Trial) demonstrated that intensive insulin therapy reducing HbA1c from 9.1% to 7.4% in T1DM reduced retinopathy risk by 76%, nephropathy by 50%, and neuropathy by 60%. The UK Prospective Diabetes Study (UKPDS) showed equivalent microvascular benefit in T2DM. These benefits persist for decades after the period of intensive control (the 'legacy effect').
• Flexible dosing capability: Modern basal-bolus insulin regimens allow dose adjustment for varying meals, activity levels, illness, and travel — enabling a lifestyle approach to glucose management rather than a rigid meal-timed schedule.
• No dose ceiling: Unlike most oral agents, insulin has no maximum effective dose. As insulin resistance or beta cell failure progresses, doses can be increased to maintain glycaemic control.
• Effective in all stages of diabetes: Insulin retains efficacy regardless of diabetes duration, degree of beta cell failure, or degree of insulin resistance — it is always capable of lowering blood glucose when dosed appropriately.
• Benefits of CGM integration: Using real-time CGM with insulin therapy (particularly in T1DM) significantly reduces hypoglycaemia rates, improves TIR, reduces HbA1c, and decreases diabetes-related hospitalisation. Multiple large trials (DIAMOND, GOLD, IMPACT) confirm CGM benefits in T1DM.
• Closed-loop systems improve outcomes markedly: AID systems (CamAPS FX, Omnipod 5) improve TIR by an average of 12-15 percentage points versus standard insulin therapy, reduce time in hypoglycaemia by 35-50%, improve sleep quality, and reduce the burden of diabetes management decisions significantly.
• Gestational benefits: Insulin in GDM reduces rates of macrosomia, shoulder dystocia, neonatal hypoglycaemia, caesarean section, and neonatal intensive care admission.

Insulin therapy carries important risks that require patient education, monitoring protocols, and management strategies:

Hypoglycaemia — The Primary Risk

Hypoglycaemia (blood glucose <3.9 mmol/L / 70 mg/dL) is the most clinically significant risk of insulin therapy. It is classified as:

• Level 1 (mild): BG 3.0-3.9 mmol/L — symptomatic (sweating, tremor, palpitations, hunger) or detected by CGM; self-treatable
• Level 2 (clinically significant): BG <3.0 mmol/L (<54 mg/dL) — requires immediate treatment regardless of symptoms
• Level 3 (severe): BG at any level causing cognitive impairment, seizure, or loss of consciousness requiring third-party assistance

Hypoglycaemia management: Mild-to-moderate hypoglycaemia is treated with the '15-15 rule' — 15 grams of fast-acting glucose (glucose tablets, juice, regular soft drink), wait 15 minutes, recheck glucose. Severe hypoglycaemia: glucagon (glucagon injection kit, or nasal glucagon — Baqsimi) administered by a third party, followed by emergency services if needed.

Risk factors for hypoglycaemia include irregular meals, strenuous unplanned exercise, alcohol consumption, renal impairment (reducing insulin clearance), and hypoglycaemia unawareness (loss of warning symptoms after recurrent episodes).

Weight Gain

Insulin therapy is associated with weight gain of 2-5 kg after initiation, due to improved glucose utilisation, reduced glycosuria, and anabolic effects. Weight gain can be minimised by combining insulin with a GLP-1 receptor agonist (e.g., semaglutide), which promotes satiety and weight loss, and by dietary counselling.

Injection Site Reactions

• Lipohypertrophy: Subcutaneous fat accumulation at repeatedly used injection sites. Impairs insulin absorption (erratic glucose levels). Prevented by rotating injection sites systematically. Existing lipohypertrophy resolves over months with site rotation.
• Lipoatrophy: Rare subcutaneous fat loss — more common with older human insulin formulations; rare with modern analogues.
• Local reactions: Redness, itching, and bruising at injection sites are common initially and usually resolve within weeks.

Diabetic Ketoacidosis (DKA) Risk with Insulin Omission

In T1DM, omitting insulin (even for a short period) rapidly leads to DKA due to absolute insulin deficiency. 'Insulin omission' is a significant cause of DKA admissions, particularly in adolescents and young adults. Sick-day management rules (never stop insulin during illness; adjust dose based on blood glucose and ketone monitoring) are essential education points.

Structured monitoring of glycaemic control and diabetes-related complications is integral to insulin therapy management.

Glycaemic Monitoring

• HbA1c: Measured every 3 months until glycaemic target is achieved, then every 3-6 months. HbA1c reflects average blood glucose over the preceding 2-3 months and is the primary outcome measure for chronic diabetes management.
• Self-monitoring of blood glucose (SMBG): For patients not using CGM, fasting blood glucose monitoring guides basal insulin dose titration. Postprandial glucose monitoring (1-2 hours after meals) guides bolus insulin dose. Frequency varies from 2-4 times daily (minimum for basal-bolus) to multiple daily checks.
• Continuous glucose monitoring (CGM): Daily or continuous real-time data viewed by patients and downloaded by clinicians at appointments. CGM reports (ambulatory glucose profile — AGP) display TIR, TBR, TAR (time above range), GMI, and variability over the past 14 days. CGM data should be downloaded and reviewed at every diabetes appointment for CGM users.
• Insulin dose titration: Basal insulin is adjusted using validated titration algorithms — commonly the '2 units every 3 days' rule (increase basal by 2 units every 3 days until fasting glucose is 4.4-7.2 mmol/L). Bolus insulin is adjusted using an insulin:carbohydrate ratio and a correction factor (insulin sensitivity factor).

Annual Diabetes Complications Screening

• Diabetic retinopathy: Annual fundal photography or dilated eye examination
• Diabetic nephropathy: Annual urine albumin:creatinine ratio (ACR) and eGFR
• Diabetic neuropathy: Annual foot examination including 10g monofilament testing, vibration, and ankle reflexes
• Cardiovascular risk: Blood pressure, lipid profile, cardiovascular risk score assessment; statin and ACE inhibitor/ARB use where indicated
• Thyroid function (T1DM): Annual TSH — autoimmune thyroid disease is more prevalent in T1DM

The cost of insulin therapy is a critical healthcare equity issue. Insulin costs vary enormously between countries and healthcare systems, with unaffordable insulin a leading cause of adverse outcomes and death in low- and middle-income countries (LMICs). The WHO and IDF have identified insulin access as a global health priority.

Insulin Costs by Country

• USA (without insurance): The USA has the highest insulin prices globally. Biosimilar glargine (Basaglar) costs approximately USD 100-150 per vial (1,000 units); branded Lantus approximately USD 280-320 per vial. The Inflation Reduction Act (2022) capped Medicare insulin copays at USD 35/month. Manufacturer cap programmes (Eli Lilly, Novo Nordisk, Sanofi) limit out-of-pocket costs for eligible patients to USD 35/month.
• UK (NHS): Insulin is available on NHS prescription for approximately GBP 9.90 per item (standard prescription charge; free for people with diabetes in England). Full NHS funding covers insulin analogues, pens, CGM (for T1DM and qualifying T2DM patients), and pump therapy.
• Europe: Generally covered by national health insurance with low patient copayments. CGM for T1DM is funded in most EU countries.
• India: Human insulin (NPH, regular) is available for INR 40-100 per vial (USD 0.50-1.20) through government programmes; insulin analogues (glargine, aspart) cost INR 400-1,200 per vial privately. CGM (FreeStyle Libre) costs approximately INR 3,500-4,500 per sensor (14 days).
• LMICs: WHO Prequalification Programme and generic/biosimilar insulin production (Biocon in India; Wockhardt) aim to reduce costs in LMICs.

CGM and Pump Costs

• FreeStyle Libre 3: Approximately USD 50-70 per sensor (14 days) in the USA; EUR 40-65 in Europe; INR 3,500-4,500 in India. Annual cost: USD 1,300-1,800
• Dexcom G7: Approximately USD 350-400 per month (10 sensors) in USA; covered by NHS for T1DM in UK
• Insulin pumps (CSII): USD 4,000-7,000 upfront plus USD 2,000-4,000/year in consumables. Covered by NHS for eligible T1DM patients in the UK; insurance-dependent in the USA
• AID systems (Omnipod 5, CamAPS FX): Omnipod 5 approximately USD 5,000-7,000/year total system cost in USA; covered by NHS in UK for eligible patients

In T1DM, there is no effective alternative to exogenous insulin for glucose control. However, in T2DM and other contexts, several evidence-based alternatives or complementary agents can reduce insulin requirements or delay insulin initiation:

• GLP-1 receptor agonists (semaglutide subcutaneous/oral — Ozempic/Rybelsus; liraglutide — Victoza; dulaglutide — Trulicity; tirzepatide — Mounjaro): The ADA/EASD 2023 consensus algorithm positions GLP-1 receptor agonists as the preferred injectable agent before insulin in T2DM. They reduce HbA1c by 1.5-2.5%, produce significant weight loss (6-15% with semaglutide; 15-22% with tirzepatide), and have proven cardiovascular and renal protective effects. Tirzepatide (dual GIP/GLP-1 agonist) produces the most potent glucose lowering and weight loss of any non-insulin agent currently available. Some patients who begin insulin can reduce or discontinue it after starting GLP-1 receptor agonists due to weight loss and improved insulin sensitivity.
• SGLT2 inhibitors (dapagliflozin — Forxiga; empagliflozin — Jardiance; canagliflozin — Invokana): Reduce HbA1c by 0.5-1.0%; produce weight loss and reduce cardiovascular (empagliflozin EMPA-REG OUTCOME trial) and renal events. Can be combined with insulin in T2DM to reduce insulin dose requirements. Note: SGLT2 inhibitors in T1DM carry a risk of euglycaemic DKA — off-label use in T1DM requires very careful patient selection and education.
• Metformin: Reduces hepatic glucose production; usually first-line in T2DM; modest HbA1c reduction (1-1.5%). Often continued alongside insulin in T2DM to mitigate insulin-related weight gain. Contraindicated below eGFR 30 mL/min/1.73m2.
• Islet cell transplantation: Pancreatic islet cells harvested from cadaveric donors and infused into the portal vein, engrafting in the liver. Can restore endogenous insulin secretion in T1DM, achieving insulin independence in approximately 40-60% of recipients at 3 years. Limited by donor availability, requirement for lifelong immunosuppression, and centre availability. Suitable for selected T1DM patients with severe hypoglycaemia unawareness and frequent severe hypoglycaemia.
• Whole pancreas transplantation: Surgical transplantation of a donor pancreas; performed simultaneously with kidney transplantation (SPK — simultaneous pancreas-kidney) in T1DM patients with end-stage renal disease. Achieves long-term insulin independence in 75-80% of recipients at 5 years. Major surgery requiring lifelong immunosuppression.